公司资料
Geron 股价、新闻与催化剂
- 股票代码:
- GERN
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
1.53 USD (+4.08%)
收盘价
最后更新: 2026年8月17日
751M USD
市值
股价为何变动
The latest monitored company update is “Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).” The corresponding closing-price reaction is not yet available.
公司概览
Telomerase-Targeted Hematology Company
Geron is a commercial-stage biopharmaceutical company focused on blood cancers. Its scientific and commercial strategy is built around inhibiting telomerase, an enzyme involved in the continued proliferation of malignant cells.
RYTELO in Lower-Risk MDS
RYTELO, or imetelstat, is a first-in-class oligonucleotide telomerase inhibitor approved in the United States and European Union for defined adults with transfusion-dependent anemia caused by lower-risk myelodysplastic syndromes. The therapy is administered by intravenous infusion every four weeks.
Differentiated Clinical Profile
RYTELO is intended for patients who have not responded to, have lost response to or are ineligible for erythropoiesis-stimulating therapy. Evidence from the Phase 3 IMerge study supports its ability to produce periods of red-blood-cell transfusion independence, making reduction of transfusion burden central to its clinical value proposition.
Commercialization Footprint
Geron directly commercializes RYTELO in the United States and is assessing how best to commercialize the product in Europe while preserving the economics and pricing integrity of the broader franchise.
未来催化剂
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。